Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and clinical activity study of mRNA-3927 in participants with propionic acidemia previously enrolled in mRNA-3927-P101
NL-OMON58817Phase 2Not yet recruiting
- Sponsor
- Moderna Inc
- Start
- Jun 2026
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mRNA-3927 in propionic acidemia (PA), sponsored by Moderna Inc. Primary endpoint: Incidence and severity of adverse events. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
mRNA-3927
03
Conditions
propionic acidemia (PA)
Beyond the preview
Go deeper on NL-OMON58817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58817.